RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Outlook Therapeutics - Stock

Outlook Therapeutics EBIT 2024

Outlook Therapeutics EBIT

-69.58 M USD

Ticker

OTLK

ISIN

US69012T2069

WKN

A2PF3C

In 2024, Outlook Therapeutics's EBIT was -69.58 M USD, a 30.97% increase from the -53.13 M USD EBIT recorded in the previous year.

The Outlook Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e253.59
2027e90.47
2026e-7.01
2025e-60.14
2024e-69.58
2023-53.13
2022-63.07
2021-51.73
2020-36.31
2019-25.03
2018-29.64
2017-35.88
2016-51.35
2015-46.56
2014-12.39

Outlook Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Outlook Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Outlook Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Outlook Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Outlook Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Outlook Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Outlook Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Outlook Therapeutics’s growth potential.

Outlook Therapeutics Revenue, Profit, and EBIT History

DateOutlook Therapeutics RevenueOutlook Therapeutics EBITOutlook Therapeutics Net Income
2029e430.35 M undefined0 undefined124.17 M undefined
2028e382.37 M undefined253.59 M undefined76.89 M undefined
2027e208.57 M undefined90.47 M undefined29.13 M undefined
2026e65.03 M undefined-7.01 M undefined-37.97 M undefined
2025e10.58 M undefined-60.14 M undefined-60.17 M undefined
2024e0 undefined-69.58 M undefined-226.44 M undefined
20230 undefined-53.13 M undefined-58.98 M undefined
20220 undefined-63.07 M undefined-66.05 M undefined
20210 undefined-51.73 M undefined-53.16 M undefined
20200 undefined-36.31 M undefined-48.87 M undefined
20198.15 M undefined-25.03 M undefined-36.04 M undefined
20183.09 M undefined-29.64 M undefined-48.02 M undefined
20173.81 M undefined-35.88 M undefined-40.03 M undefined
20162.98 M undefined-51.35 M undefined-63.14 M undefined
20155.22 M undefined-46.56 M undefined-53 M undefined
20149.05 M undefined-12.39 M undefined-20.66 M undefined

Outlook Therapeutics stock margins

The Outlook Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Outlook Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Outlook Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Outlook Therapeutics's sales revenue. A higher gross margin percentage indicates that the Outlook Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Outlook Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Outlook Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Outlook Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Outlook Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Outlook Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Outlook Therapeutics Margin History

Outlook Therapeutics Gross marginOutlook Therapeutics Profit marginOutlook Therapeutics EBIT marginOutlook Therapeutics Profit margin
2029e0 %0 %28.85 %
2028e0 %66.32 %20.11 %
2027e0 %43.38 %13.97 %
2026e0 %-10.78 %-58.38 %
2025e0 %-568.56 %-568.85 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %-307.25 %-442.42 %
20180 %-960.11 %-1,555.22 %
20170 %-941.37 %-1,050.14 %
20160 %-1,723.29 %-2,119.04 %
20150 %-892.14 %-1,015.45 %
20140 %-136.93 %-228.26 %

Outlook Therapeutics Aktienanalyse

What does Outlook Therapeutics do?

Outlook Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for eye diseases. The company was originally established in 2010 under the name Oncobiologics. Initially, the company focused on the development of biosimilar products to improve access and reduce costs of biologics. The goal was to bring cheaper alternatives to the market that were equivalent to approved original products. In 2018, the company decided to shift its focus to the development of ophthalmological therapeutics. Oncobiologics was rebranded as Outlook Therapeutics Inc, and the development of biosimilar products was discontinued. Instead, the company has since been focused on researching and developing eye therapies to provide better treatment options for patients with serious eye diseases. The business model of Outlook Therapeutics Inc is primarily based on the development and marketing of high-quality, patented medications for eye diseases. The company utilizes innovative technologies and research approaches to maximize the effectiveness and safety of its products. It works closely with leading experts and clinicians in the field of ophthalmology to ensure that the therapies meet the needs of patients. One of the key areas of Outlook Therapeutics Inc is the development of therapeutics for wet age-related macular degeneration (AMD). Wet AMD is a progressive degenerative eye disease that can lead to rapid vision deterioration. Currently, there are already various medications on the market for treating this condition. However, Outlook Therapeutics Inc is working on developing new therapeutics that have improved effectiveness, longer duration of action, and fewer side effects than existing medications. Another important area for the company is the development of therapeutics for diabetic macular edema, a disease that can occur in individuals with type 2 diabetes. The company is researching improved treatments for this condition, which can often lead to blindness. Outlook Therapeutics Inc offers a variety of products aimed at improving patients' visual capabilities. In addition to the aforementioned medications, the company also provides medication combinations and drugs with special active ingredients. Through continuous research and development, Outlook Therapeutics Inc constantly expands and optimizes its offerings to meet the needs of patients in the field of eye therapy. Overall, the business model of Outlook Therapeutics Inc is focused on advancing the research and development of new therapies for eye diseases. Through innovative technologies and collaboration with experts in the field of ophthalmology, the company aims to improve the quality of life for patients with severe eye diseases and provide them with better treatment options. Outlook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Outlook Therapeutics's EBIT

Outlook Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Outlook Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Outlook Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Outlook Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Outlook Therapeutics Stock

How much did Outlook Therapeutics achieve in EBIT for the current year?

In the current year, Outlook Therapeutics has achieved an EBIT of -69.58 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Outlook Therapeutics.

How has the EBIT of Outlook Therapeutics developed in recent years?

The EBIT of Outlook Therapeutics has increased by 30.967% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Outlook Therapeutics?

The EBIT of Outlook Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Outlook Therapeutics pay?

Over the past 12 months, Outlook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Outlook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Outlook Therapeutics?

The current dividend yield of Outlook Therapeutics is .

When does Outlook Therapeutics pay dividends?

Outlook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Outlook Therapeutics?

Outlook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Outlook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Outlook Therapeutics located?

Outlook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Outlook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Outlook Therapeutics from 6/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/29/2024.

When did Outlook Therapeutics pay the last dividend?

The last dividend was paid out on 6/29/2024.

What was the dividend of Outlook Therapeutics in the year 2023?

In the year 2023, Outlook Therapeutics distributed 0 USD as dividends.

In which currency does Outlook Therapeutics pay out the dividend?

The dividends of Outlook Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Outlook Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Outlook Therapeutics

Our stock analysis for Outlook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Outlook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.